Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)

被引：0

作者：

Hernando-Cubero, J. ^{[1
]}

Manzano, J. L. ^{[2
]}

Benavent, M. ^{[3
]}

Lopez, C. ^{[4
]}

Teule, R. ^{[5
]}

Garcia-Carbonero, R. ^{[6
]}

Carmona-Bayonas, A. ^{[7
]}

Crespo, G. ^{[8
]}

Cubillo, A. ^{[9
]}

Jimenez-Fonseca, P. ^{[10
]}

LaCasta, A. ^{[11
]}

Capdevila, J. ^{[1
]}

机构：

[1] Vall dHebron Univ Hosp, Barcelona, Spain

[2] Inst Catala Oncol Badalona, Barcelona, Spain

[3] Hosp Virgen del Rocio, Seville, Spain

[4] Hosp Univ Marques de Valdecilla, Santander, Spain

[5] Inst Catala Oncol Hosp, Barcelona, Spain

[6] Hosp Univ 12 Octubre, Madrid, Spain

[7] HJM Morales Meseguer, Murcia, Spain

[8] Hosp Univ Burgos, Burgos, Spain

[9] Hosp Univ Madrid Sanchinarro, Madrid, Spain

[10] Hosp Univ Cent Asturias, Oviedo, Spain

[11] Hosp Univ Donostia, San Sebastian, Spain

来源：

关键词：

durvalumab; tremelimumab; neuroendocrine; immunotherapy;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

J10

引用

页码：228 / 228

页数：1